Literature DB >> 18089646

Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-glass opacity.

Yukihiro Yoshida1, Akiko Kokubu, Kenji Suzuki, Hidehiko Kuribayashi, Koji Tsuta, Yoshihiro Matsuno, Masahiko Kusumoto, Yae Kanai, Hisao Asamura, Setsuo Hirohashi, Tatsuhiro Shibata.   

Abstract

BACKGROUND: High-resolution computed tomography (HRCT) of lung adenocarcinoma at early stage shows pure ground-glass opacity (GGO) and most cases of pure GGO remain stable during follow-up. There is no consensus on the strategy for follow-up. Identification of the molecular mechanisms that are associated with the natural history of lung adenocarcinoma should provide useful information.
METHODS: Twenty-three lung adenocarcinomas that were followed-up for more than 6 months pre-operatively by HRCT were included in this study. Patterns of radiological changes during the follow-up period were classified into three groups; type 1, pure GGO without consolidation; type 2, appearance or increase in consolidation within pure GGO; type 3, consolidation without pure GGO. Mutational analysis of the epidermal growth factor receptor (EGFR) and K-ras genes and immunohistochemical staining of p53 protein were performed.
RESULTS: EGFR mutations were found in 17 cases (74%), and there was no K-ras mutation. Positive staining of p53 was found in 8 cases (35%). As for radiological findings during the follow-up period, the frequencies of EGFR mutations and positive p53 staining were 67 and 0% in type 1 (n = 9), 89 and 44% in type 2 (n = 9) and 60 and 80% in type 3 (n = 5).
CONCLUSIONS: EGFR mutations were frequently found in lung adenocarcinoma with GGO on HRCT in this study. Inactivation of p53 may be associated with the appearance of central consolidation within pure GGO on HRCT which reflects invasive features and may be useful as a molecular marker during the follow-up of pure GGO.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18089646     DOI: 10.1093/jjco/hym139

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  12 in total

Review 1.  Whack-a-mole strategy for multifocal ground glass opacities of the lung.

Authors:  Kenji Suzuki
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 2.  Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology.

Authors:  Jian-Wei Gao; Stefania Rizzo; Li-Hong Ma; Xiang-Yu Qiu; Arne Warth; Nobuhiko Seki; Mizue Hasegawa; Jia-Wei Zou; Qian Li; Marco Femia; Tang-Feng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2017-02

3.  Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.

Authors:  Su Jin Hong; Tae Jung Kim; Yo Won Choi; Jeong-Soo Park; Jin-Haeng Chung; Kyung Won Lee
Journal:  Eur Radiol       Date:  2016-01-19       Impact factor: 5.315

4.  Impact of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage IA adenocarcinoma of the lung: Correlation between computed tomography images and EGFR and KRAS gene mutations.

Authors:  Tengteng Wang; Tao Zhang; Xiaoxue Han; X I Liu; Naikang Zhou; Yang Liu
Journal:  Exp Ther Med       Date:  2015-04-14       Impact factor: 2.447

Review 5.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

6.  Genomic landscape of ground glass opacities (GGOs) in East Asians.

Authors:  Peng Cao; Shan Hu; Kangle Kong; Peng Han; Jiaqi Yue; Yu Deng; Bo Zhao; Fan Li
Journal:  J Thorac Dis       Date:  2021-04       Impact factor: 2.895

Review 7.  CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis.

Authors:  Zenghui Cheng; Fei Shan; Yuesong Yang; Yuxin Shi; Zhiyong Zhang
Journal:  BMC Med Imaging       Date:  2017-01-10       Impact factor: 1.930

8.  CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation.

Authors:  Jing Zhao; Julien Dinkel; Arne Warth; Roland Penzel; Niels Reinmuth; Philipp Schnabel; Thomas Muley; Michael Meister; Heike Zabeck; Martin Steins; Jian-Yong Yang; Qian Zhou; Heinz-Peter Schlemmer; Felix J F Herth; Hans-Ulrich Kauczor; Claus Peter Heussel
Journal:  PLoS One       Date:  2017-09-26       Impact factor: 3.240

9.  The Diagnostic Value of Quantitative CT Analysis of Ground-Glass Volume Percentage in Differentiating Epidermal Growth Factor Receptor Mutation and Subtypes in Lung Adenocarcinoma.

Authors:  Hexiang Wang; Hongwei Guo; Zeguo Wang; Bao Shan; Jizheng Lin
Journal:  Biomed Res Int       Date:  2019-03-06       Impact factor: 3.411

10.  Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity.

Authors:  Sung-Jun Ko; Yeon Joo Lee; Jong Sun Park; Young-Jae Cho; Ho Il Yoon; Jin-Haeng Chung; Tae Jung Kim; Kyung Won Lee; Kwhanmien Kim; Sanghoon Jheon; Hyojin Kim; Jae Ho Lee; Choon-Taek Lee
Journal:  BMC Cancer       Date:  2014-05-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.